Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06459622
Other study ID # Chronic rhinosinusitis
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 2024
Est. completion date May 2025

Study information

Verified date March 2024
Source Assiut University
Contact Katrina Atef, General practitioner
Phone 01220058161
Email Katyatef90@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will be conducted to identify factors predicting the response of chronic rhinosinusitis with nasal polyps ( CRSwNP) to oral corticosteroids.


Description:

Treatment of nasal polyposis is divided into medical or surgical treatment . Steroids are widely used as the most effective medicine in nasal polyposis. Although oral corticosteroids are one of the frequently used treatments in the management of chronic rhinosinusitis with nasal polyps (CRSwNP), there is lack of effective means of predicting corticosteroid sensitivity in those patients. It was reported that the overall sensitivity rates of corticosteroid therapy to nasal polyps( NP) were only between 53.8% and 80%.. Many reports stated that serum and tissue interleukeine 25 (IL 25) and serum and tissue eosinophalia are good predictors to the response of CRSwNP to oral corticosteroids. Interleukeine 25(IL-25), an important epithelial-derived proinflammatory cytokine, plays various roles in different inflammatory and allergic diseases, such as asthma and atopic dermatitis . Hong et al demonstrated that the levels of IL-25 in NP tissues and in serum, as well as the NP endoscopic scores, were significantly elevated in the corticosteroid-sensitive patients compared with the non-sensitive ones. In general, eosinophilic NPs are pharmacologically glucocorticoid responsive, but non-eosinophilic or neutrophilic CRSwNP is frequently resistant to steroid treatment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 102
Est. completion date May 2025
Est. primary completion date March 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - clinical diagnosis of chronic rhinosinusitis with nasal polyps Exclusion Criteria: - 1-Patients who had taken any steroid , antihistamine or other immune-modulating medications within the past 4 weeks 2- previous nasal and sinus surgery. 3-Allergic Fungal rhinosinusitis. 4-Unilateral rhinosinusitis. 5- Antrochoanal polyps or cystic fibrosis.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Serum IL_25 and eosinophils in nasal polyp tisuee
Serum IL-25 and eosinophils in nasal polyps tisuer obtained and measured to identify the sensitivity of nasal polyps to corticosteroids

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Katrina Atef Habashy Assiut University

References & Publications (1)

Shin HW, Kim DK, Park MH, Eun KM, Lee M, So D, Kong IG, Mo JH, Yang MS, Jin HR, Park JW, Kim DW. IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2015 Jun;135(6):1476-85.e7. doi: 10.1016/j.jaci.2015.01.003. Epub 2015 Feb 25. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Eosinophils in nasal polyp tissue Eosinophils is related to the inflammatory process of CRSwNP Baseline
Primary Serum IL-25 is measured to releave the relation between them and the response of CRSwNP to oral corticosteroids Serum IL-25 is related to the effect of corticosteroids on CRSwNP Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05895929 - The Role of IL5 in Epithelial Cell Integrity Early Phase 1
Active, not recruiting NCT05891483 - Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps Phase 2
Active, not recruiting NCT04998604 - EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients Phase 4
Recruiting NCT06069310 - Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
Recruiting NCT05009758 - Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps N/A
Active, not recruiting NCT05529784 - Dupilumab in the Treatment of Severe Uncontrolled CRSwNP: a Multicentre Observational Real-life Study (DUPIREAL)
Recruiting NCT05902325 - Identifying Predictors Of Response To Mepolizumab In CRSwNP Phase 4
Completed NCT05049122 - Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52) Phase 4
Not yet recruiting NCT05598411 - CST1-Guided Oral Glucocorticoids Management for CRSwNP Phase 4
Active, not recruiting NCT05553951 - Adherence in Global Airways N/A
Recruiting NCT05131464 - The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps Phase 2
Recruiting NCT05598424 - CST1 Predictive Model of Oral Glucocorticoid Therapy Sensitivity for Chronic Rhinosinusitis With Polyps Phase 4
Active, not recruiting NCT05649813 - A Study in Male and Female Adult Participants With Chronic Rhinosinusitis With Nasal Polyps In the Greater Gulf Region
Recruiting NCT04628442 - Tissue Immune Interaction in Nasal Polyposis
Active, not recruiting NCT06118554 - 3D Printing to Improve Nasal Irrigation Outcome N/A
Active, not recruiting NCT04596189 - Dupilumab for Prevention of Recurrence of CRSwNP After ESS Phase 4
Recruiting NCT02668861 - Effect of Oral Vitamin D3 on Chronic Rhinosinusitis Treatment in Adults With Lower Vitamin D Levels Phase 3
Active, not recruiting NCT05878093 - Dupilumab in Chinese Adult Participants With CRSwNP Phase 3
Completed NCT05931744 - The Role of Budesonide Intrapolyp Injection in the Management of Type 2 Chronic Rhinosinusitis Phase 2/Phase 3
Recruiting NCT05938972 - Real Life Study of Biologicals in Patients With Severe CRSwNP